Candidiasis, commonly known as yeast infection, is a fungal infection caused by a yeast species called Candida. The most common symptoms include irritation and discharge. Over-the-counter topical antifungals are majorly used for treating common types of candidiasis.
The global Candidiasis Market is estimated to be valued at US$ 984.8 Mn in 2023 and is expected to exhibit a CAGR of 8.8% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising incidences of candidiasis cases is one of the major factors expected to drive the growth of the Candidiasis Market during the forecast period. According to the Centers for Disease Control and Prevention (CDC), nearly 75% of all women face at least one candidiasis infection in their lifetime. Candidiasis is also commonly observed in infant's oral cavities or diapers area due to lack of healthy bacteria in their developing immune system. Growing obesity rates and increase in number of immunocompromised patients undergoing organ transplant or cancer treatment are the other major factors contributing to the growth of the Candidiasis Market.
Segment Analysis
The global candidiasis market is segmented based on infection type, treatment, route of administration, end-user, and distribution channel. By infection type, the market is divided into oropharyngeal candidiasis, vulvovaginal candidiasis, esophageal candidiasis, and others. Among these, the oropharyngeal candidiasis segment dominates the market as it is the most common fungal infection found in humans. Based on treatment, the candidiasis market is classified as antifungals, dental braces, dentures, and others. Antifungal treatment holds the largest share of the market due to its wide usage for treating candida infections.
Key Takeaways
The Global Candidiasis Market Size is expected to witness high growth over the forecast period of 2023 to 2030.
Regional analysis: The North America region holds the largest share of the candidiasis market and is expected to maintain its dominance during the forecast period. This is attributed to the presence of advanced healthcare facilities and increasing awareness regarding fungal infections in this region. Asia Pacific region is expected to witness the fastest growth rate over the forecast period owing to factors such as growing geriatric population, increasing disposable incomes, and improving healthcare infrastructure in emerging countries of this region.
The key players operating in the candidiasis market are Basilea Pharmaceutica Ltd, Astellas Pharma Inc., SCYNEXIS, Inc., NovaDigm Therapeutics, Mycovia Pharmaceuticals, Inc., Pfizer Inc, and Viatris Inc. Basilea Pharmaceutica Ltd is one of the leading players in the market with its antifungal drugs cresemba and isavuconazole offering treatment for candidiasis infections. Astellas Pharma Inc. provides antifungal drug Mycamine used for treating esophageal candidiasis. SCYNEXIS, Inc.'s novel antifungal brexanolone helps in the treatment of vulvovaginal candidiasis.
Get more insights on this topic:
https://www.dailyprbulletin.com/candidiasis-market-analysia/
Check below trending articles related to this topic:
https://allmeaninginhindi.com/unveiling-the-stealthy-threat-of-catheter-related-blood-stream-infection/
Explore more trending article related to this topic:
https://allmeaninginhindi.com/navigating-the-evolving-landscape-of-enterprise-artificial-intelligence-solutions/
Comments
0 comment